Insider buying last 90 days
No open-market insider purchases were filed for SYRE in the last 90 days.
From Form 4 filings, dated to when each was filed.
Nov 13 close
Spyre Therapeutics moved this week on third-quarter results and clinical data. The company reported a widened net loss of $96.1 million for the quarter, up from $11.2 million a year prior, with EPS of ($0.94) missing the analyst estimate of ($0.78) by $0.16. Alongside the financial update, Spyre announced positive Phase 2 SKYLINE monotherapy results for ulcerative colitis and positive Phase 2 data for SPY003 in inflammatory bowel disease, which appear to have outweighed the wider losses in investor reaction. The company also announced grants of inducement awards during the week.
SYRE closed at $109.00, up 4.9%, and sits above both its 50-day average of $90.16 and 200-day average of $75.24, with the 50-day above the 200-day. The stock trades near its 52-week high of $110.64, well above its 52-week low of $21.15, and has returned 27.2% over one month and 386.8% over the past year. The GekkoIndex reads 44.8, placing it in the Distribution zone, down 8.9 over five days. Price sits 14.8% above the Gekko Fair Value of $94.95.
The next earnings report is scheduled for 18 February 2027, 95 days away, placing it outside a typical 20-trading-day holding window. No insider, Congress, or unusual options activity appears in the respective windows. Seasonality from this point in the calendar has averaged a 1.6% gain over the next 20 trading days across 5 years, rising in 2 of them. Analyst coverage stands at 13 firms, all with buy ratings, and a consensus target of $122.53, implying 12.4% upside from current levels.
Written by AI from the Nov 9, 2026 close and checked automatically against the figures on this page.
Spyre Therapeutics scores 2 supportive, 1 mixed and 2 headwinds across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
2 supportive1 mixed2 headwinds
Above 50 and 200-day
Close $104.00 is above the 50-day ($91.48) and 200-day ($76.67) averages, and the 50-day is above the 200-day.
See the chart50.9, Neutral
Reading 50.9 is in the Neutral zone.
See the GekkoIndex8.5% above
Price is 8.5% above Gekko Fair Value (more than 5% above).
See fair valueNo data
No insider, Congress or unusual options activity in the window.
See smart moneyReports in 95 days
Next report Feb 18, 2027, 95 days away — outside a typical 20-trading-day hold.
See earnings−9.7% on average
From this point in the calendar, the next 20 trading days averaged −9.7% over 5 years, rising in 2 of them.
See seasonalityA description of current data, not a recommendation. How this page works
Spyre Therapeutics closed at $104.00 on Nov 13, 2026, +343.9% over the past year, inside a 52-week range of $22.13 to $110.64.
Use the left and right arrow keys to read daily values.
Put SYRE on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Spyre Therapeutics works on early, preclinical research aimed at treating inflammatory bowel disease, covering conditions such as ulcerative colitis and Crohn's disease. Its work centers on antibody-based candidates designed to act on specific biological targets involved in the disease, including one built to bind the a4ß7 integrin and another aimed at tumor necrosis factor-like ligand 1A. The company is best known for pursuing these antibody programs rather than for any product currently available to patients.
Spyre's pipeline extends beyond its lead candidates to include several other antibody therapies, some combining more than one mechanism of action, such as pairing anti-a4ß7 with anti-IL-23 activity, or joining anti-TL1A with anti-IL-23 components. Other candidates target IL-23 alone or use mechanisms described as novel. All of these programs remain in preclinical evaluation, meaning the company's work at this stage is research-driven rather than commercial, with no indication of existing customers or revenue-generating products.
The company was originally incorporated in 2013 under the name Aeglea BioTherapeutics, Inc., adopting the name Spyre Therapeutics, Inc. in November 2023. It is headquartered in Waltham, Massachusetts, and its shares are listed on the NASDAQ under the ticker SYRE.
Spyre Therapeutics’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 50.9, in the Neutral zone, up 1.7 points over five sessions.
Up 1.7 points over five sessions.
Reading for Nov 13, 2026
| Zone | Readings | 5 days | 20 days |
|---|---|---|---|
| Buying | 36 | +4.2% | +13.3% |
| Accumulation | 187 | +1.3% | +4.4% |
| Neutral (current zone) | 419 | +1.6% | +7.4% |
| Distribution | 48 | −0.1% | −2.0% |
| Selling | 12 | +0.8% | −8.0% |
Average SYRE share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +0.9% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
Spyre Therapeutics trades 8.5% above Gekko Fair Value of $95.85, so the shares are overvalued on Gekko’s estimate.
Gekko’s own estimate of what Spyre Therapeutics shares are worth, recalculated every trading day.
$95.85
Gekko Fair Value, Nov 14, 2026
8.5% Overvalued
At the end of Aug 2026 the price was 20.4% below the estimate.
No open-market insider purchases were filed for Spyre Therapeutics, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
No open-market insider purchases were filed for SYRE in the last 90 days.
From Form 4 filings, dated to when each was filed.
No trades in SYRE were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Spyre Therapeutics has been buying back its own shares.
From company filings.
0of the funds Gekko tracks hold SYRE.
Spyre Therapeutics reports on Feb 18, 2027 (95 days away), and beat the EPS estimate in 6 of its last 8 reports.
Feb 18, 2027
95 days away
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 4, 2026 | −$0.36 est −$0.76 | — | +9.9% |
| May 5, 2026 | −$0.74 est −$0.64 | — | +5.6% |
| Feb 19, 2026 | −$0.74 est −$0.80 | $90.49M est $142.9M | +18.1% |
| Nov 4, 2025 | −$0.15 est −$0.68 | — | −3.9% |
| Aug 5, 2025 | −$0.49 est −$0.73 | — | −1.2% |
| May 8, 2025 | −$0.60 est −$0.84 | — | +10.9% |
| Feb 28, 2025 | −$0.81 est −$0.89 | — est $3.00M | −2.3% |
| Nov 7, 2024 | −$1.36 est −$0.82 | — est $2.63M | +5.6% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Analysts’ average 12-month price target for Spyre Therapeutics is $122.67, +18.0% from the last close, from 13 firms rating the stock in the last 90 days.
Each firm’s latest rating in the last 90 days: 13 firms.
| Date | Firm | Target | vs price |
|---|---|---|---|
| Nov 12 | J.P. Morgan | $116 | +11.5% |
| Nov 4 | Stifel Nicolaus | $131 | +26.0% |
| Nov 4 | Wells Fargo | $115 | +10.6% |
| Nov 4 | JonesTrading | $130 | +25.0% |
| Nov 4 | BTIG | $121 | +16.3% |
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Over the next 20 trading days from Nov 14, Spyre Therapeutics averaged −9.7% across the last 5 years, rising in 2 of them.
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | −8.0% | 1 of 5 |
| Next 10 trading days | +5.8% | 2 of 5 |
| Next 15 trading days | −0.7% | 2 of 5 |
| Next 20 trading days | −9.7% | 2 of 5 |
| Next 30 trading days | −3.5% | 2 of 5 |
For scale, SYRE’s typical 20-trading-day move in either direction is about 16%.
Spyre Therapeutics’s market cap is $9.88B and revenue of $0 over the last twelve months.
Coverage of Spyre Therapeutics this week reads negative: 1 positive, 0 neutral and 2 negative headlines.
Spyre Therapeutics’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| LLYEli Lilly | Neutral | 24.0% above |
| JNJJohnson & Johnson | Neutral | 4.4% above |
| ABBVAbbVie | Neutral | 23.7% above |
| MRKMerck | Neutral | 8.2% below |
| AZNAstraZeneca | Neutral | 34.6% below |
| PFEPfizer | Accumulation | 8.9% below |
A peer links to its own page where one exists.
Spyre Therapeutics’s market cap is $9.88B at the Nov 13, 2026 close of $104.00, with 94.97M shares outstanding.
The consensus analyst 12-month price target for Spyre Therapeutics is $122.67, +18.0% from the last close. Of the 13 firms that rated the stock in the last 90 days, 13 rate it a buy, 0 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
On Gekko’s estimate Spyre Therapeutics is overvalued: the Nov 13, 2026 close of $104.00 is 8.5% above Gekko Fair Value of $95.85. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
Spyre Therapeutics is expected to report on Feb 18, 2027 (95 days away). Analysts expect earnings of −$1.01 per share. Spyre Therapeutics beat the earnings estimate in 6 of its last 8 reports, moving 7.2% on average across the report.
Spyre Therapeutics’s 52-week high is $110.64 and its 52-week low is $22.13; it closed at $104.00 on Nov 13, 2026, +343.9% over the past year. Over the last five years the shares peaked at $181.82 on Nov 16, 2021.
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 2 of the 5 items with data read as supportive (trend and earnings risk), 1 as mixed (gekkoindex) and 2 as headwinds (fair value and seasonality). The checklist is a description of current data, not a recommendation.
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,475 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.Type a ticker or company name. Press Esc to close.